Clinical trial
Factor Xa Inhibitor YM150 for the Prevention of Blood Clot Formation in Veins…
NCT00353678 · Astellas Pharma Inc, Industry · Completed
Key facts
| NCT number | NCT00353678 |
|---|---|
| Title | Factor Xa Inhibitor YM150 for the Prevention of Blood Clot Formation in Veins After Scheduled Hip Replacement (ONYX-2) |
| Official title | Direct Factor Xa Inhibitor YM150 for Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Hip Replacement.---A Double Blind, Parallel, Dose-finding Study in Comparison With Open Label Enoxaparin |
| Lead sponsor | Astellas Pharma Inc, Industry |
| Collaborators | Astellas Pharma Europe B.V. Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Thromboembolism |
| Intervention type | Drug |
| Interventions | YM150 |
| Enrollment | 1,141 |
| Start date | Jun 1, 2006 |
| Primary completion | Aug 1, 2007 |
| Completion | Aug 1, 2007 |
| First posted | Jul 19, 2006 |
| Last update posted | Mar 21, 2013 |
| Countries | Austria, Bosnia and Herzegovina, Czechia, Denmark, Finland, Germany, Greece, Italy, Latvia, Lithuania, Norway, Poland and 5 more |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: